Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland

Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland

Show other versions (1)

In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion. While in certain types of tumors an *NTRK* gene fusion is...

Full description

Bibliographic Details
Main Authors: Holger Moch, Gieri Cathomas, Milo Frattini, Wolfram Jochum, Erik Vassella, Laurence de Leval, Joachim Diebold, Christian Britschgi, Thomas McKee, Lukas Bubendorf
Format: Article
Language:English
Published: THE HEALTHBOOK COMPANY LTD. 2021-03-01
Series:healthbook TIMES. Oncology Hematology
Online Access:https://doi.org/10.36000/hbT.OH.2021.07.030

Similar Items

Similar Items